FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway

Journal of Neuroimmunology

Volumn 270, Issue 1-2, 2014, Pages 13-21

  Ntranos, Achilles ^a   Hall, Olivia ^b   Robinson, Dionne P ^b   Grishkan, Inna V ^a   Schott, Jason T ^a   Tosi, Dominique M ^a   Klein, Sabra L ^b   Calabresi, Peter A ^a   Gocke, Anne R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Autoimmunity; Experimental autoimmune encephalomyelitis (EAE); Fingolimod (FTY720); Murine influenza; Viral infection

Indexed keywords

AUTOIMMUNITY; CD8+ T CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE); FINGOLIMOD (FTY720); MURINE INFLUENZA; VIRAL INFECTION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHEMOTAXIS, LEUKOCYTE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLOW CYTOMETRY; GRANZYMES; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INTERFERON-GAMMA; LYSOPHOSPHOLIPIDS; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; PROPYLENE GLYCOLS; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84898776438     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.03.007     Document Type: Article

References (41)

1. Aktas O., Ullrich O., Infante-Duarte C., Nitsch R., Zipp F. Neuronal damage in brain inflammation. Arch. Neurol. 2007, 64:185-189.
2. Billich A., Bornancin F., Devay P., Mechtcheriakova D., Urtz N., Baumruker T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem. 2003, 278:47408-47415.
3. Boulton C., Meiser K., David O.J., Schmouder R. Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study. J. Clin. Pharmacol. 2012, 52:1879-1890.
4. Bourdette D., Gilden D. Fingolimod and multiple sclerosis: four cautionary tales. Neurology 2012, 79:1942-1943.
5. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br. J. Pharmacol. 2009, 158:1173-1182.
6. Brinkmann V., Billich A., Baumruker T., Heining P., Schmouder R., Francis G., et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 2010, 9:883-897.
7. Burgermeister E., Endl J., Scheuer W.V. Activation of cytosolic phospholipase A2 in human T-lymphocytes involves inhibitor-kappaB and mitogen-activated protein kinases. Eur. J. Pharmacol. 2003, 466:169-180.
8. Chiba K., Kataoka H., Seki N., Shimano K., Koyama M., Fukunari A., et al. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-beta in mouse experimental autoimmune encephalomyelitis. Int. Immunopharmacol. 2011, 11:366-372.
9. Cohen J.A., Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann. Neurol. 2011, 69:759-777.
10. Cohen J.A., Barkhof F., Comi G., Hartung H.P., Khatri B.O., Montalban X., et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:402-415.
11. Comi G., O'Connor P., Montalban X., Antel J., Radue E.W., Karlsson G., et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult. Scler. 2010, 16:197-207.
12. Friese M.A., Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann. Neurol. 2009, 66:132-141.
13. Gocke A.R., Lebson L.A., Grishkan I.V., Hu L., Nguyen H.M., Whartenby K.A., et al. Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis. J. Immunol. 2012, 188:5877-5886.
14. Gross C.M., Baumgartner A., Rauer S., Stich O. Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Neurology 2012, 79:2006-2007.
15. Huseby E.S., Huseby P.G., Shah S., Smith R., Stadinski B.D. Pathogenic CD8 T cells in multiple sclerosis and its experimental models. Front. Immunol. 2012, 3:64.
16. Janas M.L., Groves P., Kienzle N., Kelso A. IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation. J. Immunol. 2005, 175:8003-8010.
17. Kappos L., Radue E.W., O'Connor P., Polman C., Hohlfeld R., Calabresi P., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:387-401.
18. Kataoka H., Sugahara K., Shimano K., Teshima K., Koyama M., Fukunari A., et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell. Mol. Immunol. 2005, 2:439-448.
19. Kelley D.S., Taylor P.C., Nelson G.J., Mackey B.E. Arachidonic acid supplementation enhances synthesis of eicosanoids without suppressing immune functions in young healthy men. Lipids 1998, 33:125-130.
20. Kharel Y., Lee S., Snyder A.H., Sheasley-O'neill S.L., Morris M.A., Setiady Y., et al. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J. Biol. Chem. 2005, 280:36865-36872.
21. Khatri B., Barkhof F., Comi G., Hartung H.P., Kappos L., Montalban X., et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011, 10:520-529.
22. Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm. Venereol. Suppl. 1989, 151:7-10. (discussion 47-52).
23. Leypoldt F., Munchau A., Moeller F., Bester M., Gerloff C., Heesen C. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology 2009, 72:1022-1024.
24. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002, 296:346-349.
25. Meno-Tetang G.M., Li H., Mis S., Pyszczynski N., Heining P., Lowe P., et al. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab. Dispos. 2006, 34:1480-1487.
26. Nelson G.J., Schmidt P.C., Bartolini G., Kelley D.S., Phinney S.D., Kyle D., et al. The effect of dietary arachidonic acid on plasma lipoprotein distributions, apoproteins, blood lipid levels, and tissue fatty acid composition in humans. Lipids 1997, 32:427-433.
27. Niknami M., Patel M., Witting P.K., Dong Q. Molecules in focus: cytosolic phospholipase A2-alpha. Int. J. Biochem. Cell Biol. 2009, 41:994-997.
28. Payne S.G., Oskeritzian C.A., Griffiths R., Subramanian P., Barbour S.E., Chalfant C.E., et al. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood 2007, 109:1077-1085.
29. Ratchford J.N., Costello K., Reich D.S., Calabresi P.A. Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology 2012, 79:2002-2004.
30. Reed L.J., Meunch H. A simple method of estimating 50 percent endpoints. Am. J. Hyg. 1938, 27:493.
31. Robinson D.P., Lorenzo M.E., Jian W., Klein S.L. Elevated 17beta-estradiol protects females from influenza A virus pathogenesis by suppressing inflammatory responses. PLoS Pathog. 2011, 7:e1002149.
32. Saida T., Kikuchi S., Itoyama Y., Hao Q., Kurosawa T., Nagato K., et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult. Scler. 2012, 18(9):1269-1277.
33. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
34. Singer B., Ross A.P., Tobias K. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis. Int. J. Clin. Pract. 2011, 65:887-895.
35. Solito E., De Caterina R., Giannessi D., Paggiaro P.L., Sicari R., Parente L. Studies on the induction of lipocortin-1 by glucocorticoids. Ann. Ist. Super. Sanita 1993, 29:391-394.
36. Sun D., Whitaker J.N., Huang Z., Liu D., Coleclough C., Wekerle H., et al. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J. Immunol. 2001, 166:7579-7587.
37. Uccelli A., Ginocchio F., Mancardi G.L., Bassetti M. Primary varicella zoster infection associated with fingolimod treatment. Neurology 2011, 76:1023-1024.
38. Warnke C., Stuve O., Hartung H.P., Fogdell-Hahn A., Kieseier B.C. Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis. Neuropsychiatr. Dis. Treat. 2011, 7:519-527.
39. Webb M., Tham C.S., Lin F.F., Lariosa-Willingham K., Yu N., Hale J., et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. 2004, 153:108-121.
40. Zemann B., Kinzel B., Muller M., Reuschel R., Mechtcheriakova D., Urtz N., et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 2006, 107:1454-1458.
41. Zhang Z.Y., Zhang Z., Schluesener H.J. FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis. Neuropathol. Appl. Neurobiol. 2009, 35:487-495.